

CVCT

6th Global CardioVascular Clinical Trialists Forum



Course Directors: Faiez ZANNAD, Nancy - FRA & Bertram PITT, Ann Arbor - USA

3-5
DECEMBER
2009

PARIS, France
Pullman Tour Eiffel

First announcement

www.globalcvctforum.com

Co-organized with

Cardiovascular
Pharmacology
and Drug Therapy
ESC Working Group



Accreditation



Under the auspices of



CVCT

WHAT IS SPECIAL ABOUT CVCT MEETINGS?

- It is the keen Practitioner interest to better understand the results of recent major trials and how these should influence clinical practice.
- It is the keen Academic people interest to exchange ideas with practitioners about the relevance of ongoing research and future trials.
- It is the keen Pharmaceutical and device Industries interest to present and discuss their ongoing research and future trials with the scientific profession and with regulatory people.

Organised in collaboration with the **European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy**, CVCT Forum is a meeting specifically and totally dedicated to the discussion of clinical trials in cardiovascular disease.

CVCT Forum is attended by experts principally engaged in cardiovascular clinical trials. Participants are among the group of **major international thought leaders** and come from various primary job functions in primary care, pharmaceutical and device industry, drug and device regulatory bodies, publishing houses and health economic trends analysts from around the world.

Outstanding faculty members, each committed to producing data from controlled clinical trials that contribute to better clinical care and to discussing issues relevant to identify:

- How to do better clinical trials,
- How to satisfy regulatory authorities and,
- Most importantly, how to improve cardiovascular health care.

THE FORMAT OF THE MEETING

CVCT meetings are primarily oriented toward discussion among persons as opposed to lecturing to a broad audience. Cross-talk, breaking barriers and building bridges as opposed to dictating doctrine is the important agenda. To fulfil these aims, the sessions are structured in various formats:

- Plenary practitioner monitored expert discussion sessions
- Small interactive work sessions:
 - brainstorming workshops,
 - expert discussion,
 - how-to-sessions and,
 - consensus building workshops.

CVCT FORUM AIMS TO:

- Familiarise practitioners and young investigators with the science of clinical trials from trial protocol design to trial result interpretation,
- Examine the background of knowledge which led to the design of major trials,
- Identify and understand best evidence from clinical trials,
- Examine the consequences of trial results on the updating of guidelines,
- Consider the consequences and relative weight of Evidence based vs Mechanism based and Marketing based medicine,
- Identify emerging important issues in cardiovascular medicine,
- Examine opportunities and needs for new trials,
- Promotion of, and education about new therapies, based on scientific evidence.

CVCT meetings are accredited for Continuous Medical Education by the **European Board of Accreditation in Cardiology (EBAC)** and as a result recognized by the **American Medical Association (AMA)**.

CVCT 2009 HIGHLIGHTS:

- **Major clinical trials of the year**
- **Coronary artery disease.** Heart rate slowing Ivabradine (BEAUTIFUL, SHIFT), metabolic intervention.
- **Thrombosis:** New orally active anti-Xa and anti-thrombin agents (Dabigatran, Apixaban, Rivaroxaban), Trials in Venous Thrombo Embolism, Stroke, Atrial Fibrillation and ACS. Clopidogrel vs. newer antiplatelet agents (Cangrelor, Prasugrel). Safety vs efficacy issue.
- **Lipid lowering agents.** Moving targets. New targets (CRP JUPITER, HDL CETP inhibitors, Ezetimibe IMPROVE-IT), Combination therapy (Niacin, HPS-THRIVE2). Rosuvastatin (CENTAURUS, AURORA).
- **Diabetes and CV protection.** New drugs (GLP-1, Liraglutide, Gliptins, Sitagliptin, Vildagliptin, Saxagliptin). Gliclazide (ADVANCE), Glitazones Safety vs. Efficacy issues. Macro vs. microvascular protection. Target organs protection vs. morbidity-mortality trials. Intensive multiple risk control (ACCORD).
- **Heart failure:** Drugs on the horizon, diastology, the challenge of conducting trial in acute heart failure, new frontiers with devices.
- **New drugs acting on the ReninAngiotensin-Aldosterone system.**
 - Aliskiren (ALTITUDE, ALOFT, ASPIRE, ATMOSPHERE, ASTRONAUT).
 - Aldosterone synthase inhibitors (LCI) and aldosterone antagonists (EMPHASIS-HF).
- **Fixed combinations in hypertension and the high risk patient.** Where to fit into therapy? Polypill, Registrability.
- **Primary prevention with drug therapy (HOPE-3).**
- **Arrhythmias:** New drugs, Dronedarone (ATHENA, DIONYSOS, ANDROMEDA), Vernakalant (ACT, AVRO). New devices.
- **Stent and surgery trials.** Bare vs DES. Stent thrombosis (PROTECT), Multivessel (EXECUTIVE, SYNTAX). Special patients groups. Renal artery-stenosis trials.
- **Devices/Telemonitoring:** Trials and implementation issues
- **Transdisciplinary issues:**
 - The Cardiometabolic syndrome
 - Obesity and weight loss drugs (Sibutramine SCOUT), Diabesity
 - Cardiorenal syndrome
 - Cardio-Gerontology
- **North meets South.** Are modern trials addressing health needs worldwide?
- **East meets West.**
 - The challenge of globalization of clinical trials.
 - The emergence of Asia into trial science.
- **EMA meets FDA.**
- **The NHLBI (NIH) meets EU PCRD programs.**
- **Academia moderated industry-regulator cross talk.** Updating drug development guidelines.
- **Translational research** and future trials. Practitioner monitored academia-industry brainstorming.
- **The trialist curriculum** Young CVCTrialist sessions. Course, training, mentoring.

SCIENTIFIC SECRETARIAT

Faiez ZANNAD

Personal Assistants:

Catherine VILLEMMAIN

Stéphanie GROJEAN

CIC - INSERM

CHU de Nancy

Hôpital Jeanne d'Arc - BP 303

54201 Toul cedex

France

Ph: +33(0)3 83 65 66 25

Fax: +33(0)3 83 65 66 19

c.villemain@chu-nancy.fr

LOGISTIC ORGANIZATION

OVERCOME

3-5, bd Paul-Emile Victor

92523 Neuilly-sur-Seine cedex

France

Ph: +33 (0)1 41 92 01 20

Fax: +33 (0)1 46 41 05 21

Overcome